Novo Nordisk stock holds its ground as new obesity trial and buybacks support long-term story
Published on 08/30/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (ISIN DK0062498333) stock is drawing interest on August 30, 2026, as the Danish drugmaker pushes a new phase 3 obesity trial for Asian patients and continues a large share buyback program that underpins its long-term narrative.
Fresh obesity trial targets Asian patients
Recent local industry reporting on August 30, 2026 highlights that Novo Nordisk has begun a phase 3 trial called AMAZE 13 in overweight and obese adults in Asia for its next-generation obesity and diabetes drug candidate, aimed at following on from Wegovy.
The AMAZE 13 study is designed to enroll around 400 adults with overweight or obesity in the region and assess the percentage change in body weight at the 80-week mark, making it one of the more extended obesity trials in this population and reinforcing the company’s long-term focus on weight-loss and metabolic care.
The program follows regulatory clearance received on August 26, 2026 to run the study in Asian patients, signaling that Novo Nordisk is now moving from earlier development stages into late-stage confirmation of safety and efficacy for this candidate in the region.
Buybacks, consensus and sector positioning
Alongside its pipeline work, Novo Nordisk continues a substantial share repurchase effort that is part of a program sized at 15 billion Danish kroner, with recent data showing almost 30 million B shares already bought back by August 21, 2026 at an average price of 280.34 kroner, for a transaction value above 8.3 billion kroner.
This buyback pace means the company has already executed more than half of the planned program by late August 2026, reducing free-float and providing support to the share price at a time when valuation and expectations around obesity treatments are central to the investment case.
Market data compiled in late August 2026 indicate that the stock carries a consensus rating of Hold, with an average price target of $64.94, suggesting that, at current levels, analysts collectively see limited upside and that much of the success of Wegovy and other obesity products is already reflected in the valuation.
Separate market commentary on August 30, 2026 notes that after the strong run in Novo Nordisk and a key peer driven by obesity drug demand, attention has begun to shift to other treatment areas such as hair loss, underlining how investor focus can rotate even while the company continues to consolidate its leadership in weight management and metabolic disease.
Cardiometabolic footprint and product context
In obesity and related cardiometabolic conditions, Novo Nordisk has already secured important regulatory milestones, including a March 2024 approval for Wegovy in the United States that extended the drug’s label to reducing cardiovascular death, myocardial infarction and stroke risks in overweight or obese adults with established cardiovascular disease, deepening the strategic value of its obesity franchise.
The company’s oral GLP-1 diabetes medicine, Rybelsus, subsequently gained a similar cardiovascular risk-reduction indication in high-risk diabetes patients, anchoring the broader cardiometabolic platform that supports long-term revenue streams beyond pure weight-loss use.
These earlier approvals provide context for the new AMAZE 13 trial: investors can now view the next-generation obesity candidate not only as a potential follow-on weight-loss therapy but also as a possible contributor to the wider cardiovascular and metabolic risk-reduction portfolio if future data and regulators support such label expansions.
Representative product: Wegovy and evolving demand
Wegovy, a once-weekly injectable GLP-1 agonist for chronic weight management in adults with obesity or overweight and weight-related comorbidities, remains Novo Nordisk’s flagship obesity product and has been central to the stock’s multiyear performance story.
The drug’s profile combines significant weight-loss efficacy with a growing body of evidence around cardiometabolic benefits, which has helped drive demand both from patients and payers and positioned Novo Nordisk as a leading player in modern obesity pharmacotherapy.
As the company rolls out new phase 3 studies such as AMAZE 13 for its next-generation candidate, many investors will compare future results to Wegovy’s clinical and commercial trajectory, including the ability to sustain long-term weight reduction over 80 weeks or more, manage side effects, and potentially achieve cardiovascular risk reduction.
Stock view and market data
Novo Nordisk shares are traded primarily on the Copenhagen exchange in Danish kroner and also via listings and instruments that provide exposure for global investors; current market data as of late August 2026 show that the consensus price target of $64.94 now stands as a reference point against which the company’s continued obesity and buyback story will be measured.
With a large portion of its 15 billion kroner buyback already executed at an average repurchase price of 280.34 kroner by August 21, 2026 and the AMAZE 13 trial seeking to demonstrate weight-change outcomes at 80 weeks in roughly 400 Asian adults, Novo Nordisk stock remains closely tied to the evolution of obesity treatment demand and the company’s ability to extend its cardiometabolic franchise.
Read more
Recent coverage on Novo Nordisk share buybacks and Wegovy in China
Fact box
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NVO
Exchange: Copenhagen (primary listing)
Sector / Industry: Health Care - Pharmaceuticals
Index membership: C25 index
